Cetera Advisor Networks LLC Increases Holdings in Stryker Co. (NYSE:SYK)

Cetera Advisor Networks LLC raised its stake in Stryker Co. (NYSE:SYKFree Report) by 4.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 32,980 shares of the medical technology company’s stock after buying an additional 1,293 shares during the quarter. Cetera Advisor Networks LLC’s holdings in Stryker were worth $9,876,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of SYK. Burkett Financial Services LLC acquired a new position in Stryker in the fourth quarter valued at approximately $25,000. Farmers & Merchants Trust Co of Chambersburg PA grew its holdings in shares of Stryker by 203.3% during the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 61 shares during the period. Rogco LP acquired a new stake in shares of Stryker during the 4th quarter worth about $30,000. DSM Capital Partners LLC purchased a new stake in Stryker in the 4th quarter valued at about $34,000. Finally, HBC Financial Services PLLC acquired a new position in Stryker in the fourth quarter valued at about $37,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Stock Down 0.1 %

Shares of NYSE SYK opened at $349.33 on Friday. Stryker Co. has a 1 year low of $249.98 and a 1 year high of $361.41. The company has a market capitalization of $133.08 billion, a price-to-earnings ratio of 39.88, a price-to-earnings-growth ratio of 2.75 and a beta of 0.92. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.71 and a quick ratio of 0.99. The business has a 50-day moving average of $337.38 and a two-hundred day moving average of $328.08.

Stryker (NYSE:SYKGet Free Report) last posted its earnings results on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share for the quarter, topping the consensus estimate of $2.36 by $0.14. The firm had revenue of $5.24 billion during the quarter, compared to analysts’ expectations of $5.10 billion. Stryker had a return on equity of 23.05% and a net margin of 16.03%. The firm’s revenue was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.14 earnings per share. On average, analysts forecast that Stryker Co. will post 11.95 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Investors of record on Friday, June 28th will be given a $0.80 dividend. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.92%. The ex-dividend date is Friday, June 28th. Stryker’s dividend payout ratio (DPR) is 36.53%.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. TD Cowen boosted their price target on shares of Stryker from $365.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, April 11th. Evercore ISI boosted their target price on Stryker from $340.00 to $370.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. Wells Fargo & Company raised their price target on Stryker from $364.00 to $381.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 1st. Stifel Nicolaus boosted their price objective on Stryker from $350.00 to $375.00 and gave the company a “buy” rating in a report on Wednesday, May 1st. Finally, The Goldman Sachs Group initiated coverage on Stryker in a report on Thursday, May 30th. They set a “neutral” rating and a $372.00 target price for the company. Four investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and an average target price of $370.58.

Read Our Latest Stock Report on Stryker

Stryker Profile

(Free Report)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Recommended Stories

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYKFree Report).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.